Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Jefferies Reiterates Buy Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:01 AM ESTJefferies analyst Maury Raycroft reiterated a Buy rating and $149.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Abstract data strengthen adagrasib's 1L pembro combo profile, removing worst-case scenarios and showing positive differentiation on safety+efficacy vs AMGN. MRTX said we'll... More
Piper Sandler Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTPiper Sandler analyst Swapnil Malekar reiterated an Overweight rating and $110.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO abstract revealed that adagrasib+pembro combo in 1L NSCLC patients showed an ORR of 49%, which came in below the Street expectation of ~55%... More
JPMorgan Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $94.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO late-breaking abstracts were published this evening, including an updated look at the phase 2 KRYSTAL-7 trial (adagrasib + pembrolizumab in 1L G12C+ NSCLC). On the whole, we believe the data continue to support the regimens differentiated positioning relative to standard of care and are far more favorable than that of Lumakras + CPI.... More
Morgan Stanley Reiterates Equalweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 7:59 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Data in the abstract from the Ph2 K-7 study (adagrasib + pembro) in 1L NSCLC confirm a tolerable safety profile, as expected. That... More
